US Stock MarketDetailed Quotes
TSHA Taysha Gene Therapies
- 1.6900
- -0.1800-9.63%
Close Oct 31 16:00 ET
- 1.6900
- 0.00000.00%
Post 19:54 ET
346.35MMarket Cap-3448P/E (TTM)
1.8700High1.6800Low2.09MVolume1.8500Open1.8700Pre Close3.68MTurnover1.71%Turnover RatioLossP/E (Static)204.94MShares4.320052wk High3.18P/B206.66MFloat Cap1.270052wk Low--Dividend TTM122.28MShs Float33.3500Historical High--Div YieldTTM10.16%Amplitude0.5000Historical Low1.7570Avg Price1Lot Size
Taysha Gene Therapies Stock Forum
Sign in to post a comment
$Taysha Gene Therapies (TSHA.US)$
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Taysha Gene Therapies (Nasdaq: TSHA) has announced a public offering of up to $75 million in common stock and pre-funded warrants. This offering allows certain investors the option to purchase pre-funded warrants instead of common stock. Additionally, underwriters Jefferies, Goldman Sachs, and Cantor have a 30-day option to buy up to 15% more shares under the same...
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Taysha Gene Therapies (Nasdaq: TSHA) has announced a public offering of up to $75 million in common stock and pre-funded warrants. This offering allows certain investors the option to purchase pre-funded warrants instead of common stock. Additionally, underwriters Jefferies, Goldman Sachs, and Cantor have a 30-day option to buy up to 15% more shares under the same...
$Taysha Gene Therapies (TSHA.US)$ Taysha Gene Therapies: Tsha-102 Well-Tolerated in Both Adult Patients Treated, With No Serious Adverse Events or Dose-Limiting Toxicities
$Taysha Gene Therapies (TSHA.US)$ Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting
3 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
Company to host webcast on Tuesday, June 18, 2024, at 8:00 AM Eastern Time
Oral presentation by Elsa Rossignol, M.D., FRCP, FAAP, Principal Investigator of the REVEAL adolescent and adult trial at CHU Sainte-Justine and Colleen Buhrf...
3 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
Company to host webcast on Tuesday, June 18, 2024, at 8:00 AM Eastern Time
Oral presentation by Elsa Rossignol, M.D., FRCP, FAAP, Principal Investigator of the REVEAL adolescent and adult trial at CHU Sainte-Justine and Colleen Buhrf...
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
I Am 102927471 :